- Cruz-Correa, M., Oh, D., Kato, K., Tabernero, J., Bai, Y., Shi, J.,…Moehler, M. (2024). Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up. Annals of Oncology, 35, S893-S894. https://doi.org/10.1016/j.annonc.2024.08.1503 (Meeting abstract)
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
on 10 de juny de 2025
with No hi ha comentaris
Deixa un comentari